文献速递心脏核医学放射性药物与辐射防护

颊部咖啡因条用于逆转血管扩张剂负荷试验不良反应

Buccal caffeine strips for reversal of adverse symptoms of vasodilator stress.
PubMed 文献 · J Nucl Cardiol · 2022-07-06

在单中心11周内连续接受瑞加诺生负荷SPECT心肌灌注显像的患者中,按周交替使用静脉咖啡因60 mg或颊部咖啡因条100 mg逆转症状。仅24%患者需要逆转,颊部与静脉咖啡因在症状持续时间、严重程度和患者满意度上无显著差异,颊部组仅2例需追加静脉咖啡因。

要点

  • 颊部咖啡因条可作为逆转血管扩张剂负荷不良反应的初始策略,安全且耐受良好。
  • 颊部与静脉咖啡因组症状持续时间(152.8 vs 163.4秒,P=0.87)和满意度(2.8 vs 3.2,P=0.38)无显著差异。
  • 颊部组仅2例因持续症状和呕吐需追加静脉咖啡因,静脉组无需追加。

核心结论

  • 颊部咖啡因条是逆转血管扩张剂负荷不良反应的安全、耐受良好且有效的初始策略,适用于少数提出需求的患者。
  • 单用颊部咖啡因或联合静脉补救咖啡因在逆转不良反应方面高度有效,且无重大不良临床事件。

研究设计与样本

  • 在单一大都市医院为期11周的单中心研究,连续纳入接受瑞加诺生负荷SPECT心肌灌注显像的患者。
  • 治疗按周交替分配为静脉咖啡因60 mg或颊部咖啡因条100 mg,咖啡因在示踪剂注射至少3分钟后给予。
  • 共纳入122例患者,其中颊部咖啡因周70例(57%),静脉咖啡因周52例(43%);仅28例(24%)接受咖啡因逆转,7例(6%)接受静脉咖啡因,21例(17%)接受颊部咖啡因。

主要发现

  • 静脉与颊部咖啡因组治疗后症状持续时间无显著差异(152.8 vs 163.4秒,P=0.87)。
  • 两组初始和最终症状严重程度无显著差异。
  • 颊部组仅2例因持续症状和呕吐需追加静脉咖啡因,静脉组无患者需追加剂量。
  • 两组患者满意度无显著差异(2.8 vs 3.2,P=0.38)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Due to recurrent shortages of aminophylline, intravenous caffeine has emerged as a commonly used, safe and reliable method to treat adverse effects of vasodilator stress agents. We sought to evaluate the safety and effectiveness of buccal caffeine strips which are rapidly absorbed, inexpensive, readily available, and simplify caffeine administration. METHODS: Consecutive patients undergoing regadenoson stress SPECT MPI were assessed for the occurrence of symptoms during testing over an 11-week period at a single metropolitan hospital. Adverse symptoms, including their severity and duration, were recorded at the time of testing. Patient satisfaction was rated on a scale of 1 to 5 (5 being the most satisfied). Patients received reversal with caffeine if symptoms were felt to be significant enough by the patient and physician performing the test. The treatment received alternated week to week between IV caffeine (60 mg) or 100 mg buccal caffeine strips. Caffeine was given at least 3 minutes after tracer injection. A rescue dose of IV caffeine was offered 10 minutes later if indicated. RESULTS: Of the 122 patients enrolled in the study, 70 (57%) were included during buccal caffeine weeks and 52 (43%) during IV caffeine weeks, and only 28 (24%) received reversal with a caffeine agent. Seven (6%) received IV caffeine and 21 (17%) received buccal caffeine. There was no significant difference in symptom duration between IV and buccal caffeine after treatment (152.8 vs 163.4 seconds, P = 0.87). There was no significant difference in initial and final symptom severity between groups. Only 2 patients in the buccal group required rescue IV caffeine for ongoing symptoms and emesis. None of the IV group required a rescue dose. There was no significant difference in patient satisfaction between the groups (2.8 vs 3.2, P = 0.38). CONCLUSION: Buccal caffeine strips are a safe, well tolerated, and effective initial strategy to reverse adverse effects of vasodilator stress in the minority of patients who request it. Buccal caffeine alone or with IV rescue caffeine was highly effective in reversing adverse effects and was free of major adverse clinical events.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Elsadany M, Stringer B, Bote J, et al. Buccal caffeine strips for reversal of adverse symptoms of vasodilator stress. J Nucl Cardiol. 2022. PMID: 35794456. doi:10.1007/s12350-022-03039-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。